Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
K-ras mutation associated with duration of tamoxifen therapy, menstrual status
May 19th, 2005
The presence of a K-ras gene mutation in endometrial samples of women with breast cancer is associated with the length of time they received tamoxifen treatment and with their menstrual status, study results suggest. "The putative presence of a mutation in codon 12 of the K-ras gene was investigated in the endometrium of tamoxifen (TAM) and toremifene (TOR)-treated breast cancer patients," wrote T. Hachisuga and colleagues, Fukuoka University, Japan. "DNA was extracted from fresh cytologic samples of the endometrium in 86 TAM and 21 TOR-treated breast cancer patients. Mutations were detected by enriched polymerase chain reaction and an enzyme-linked...
Source: Women's Health Weekly (2005-05-19)
|
